Company research
HERON THERAPEUTICS, INC. /DE/
CIK 818033Updated Nov 17, 2026
HRTX price & chart
Loading TradingView…
NASDAQ:HRTX on TradingView ↗About the company
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.
In the news
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026 ↗
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value News provided by Heron Therapeutics, Inc. Aug 15, 2025, 07:45 ET Share this article Share to X Share this article Share to X CARY, N.C. , Aug. 15, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. ↗
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress News provided by Heron Therapeutics, Inc. Aug 08, 2025, 07:45 ET Share this article Share to X Share this article Share to X Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 mill ↗
Recent filings
DEFA14A filing
10-Q filing
DEFA14A filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement · Material Modification to Rights of Security Holders · Regulation FD Disclosure
Items 1.01, 3.03, 7.01, 9.01
Show 5 more recent filings
S-8 filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Entry into a Material Definitive Agreement · Material Modification to Rights of Security Holders
Items 1.01, 3.03, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 248,950,000Source | 220,777,000Source | 252,262,000Source | 232,090,000Source | 218,136,000Source | 246,216,000Source | 235,752,000Source | 217,887,000Source | 255,877,000Source | 233,147,000Source | 222,506,000Source | 250,951,000Source |
| Property, Plant and Equipment, NetUSD | 12,960,000Source | 15,414,000Source | 11,814,000Source | 13,683,000Source | 15,900,000Source | 12,025,000Source | 14,537,000Source | 19,306,000Source | 12,403,000Source | 14,863,000Source | 20,166,000Source | 22,160,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 43,068,000Source | 25,741,000Source | 20,721,000Source | 16,516,000Source | 18,386,000Source | 26,117,000Source | 19,269,000Source | 20,450,000Source | 28,647,000Source | 25,802,000Source | 28,677,000Source | 15,364,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 81,047,000Source | 67,039,000Source | 89,571,000Source | 79,931,000Source | 73,708,000Source | 83,693,000Source | 78,736,000Source | 65,322,000Source | 89,587,000Source | 78,881,000Source | 60,137,000Source | 52,049,000Source |
| Inventory, NetUSD | 70,025,000Source | 45,950,000Source | 90,585,000Source | 72,965,000Source | 42,864,000Source | 92,539,000Source | 56,932,000Source | 42,473,000Source | 92,746,000Source | 53,160,000Source | 42,110,000Source | 54,573,000Source |
| Assets, CurrentUSD | 229,400,000Source | 195,187,000Source | 229,845,000Source | 210,923,000Source | 191,168,000Source | 228,984,000Source | 212,841,000Source | 185,903,000Source | 238,066,000Source | 209,014,000Source | 188,774,000Source | 205,435,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 22,841,000Source | 11,308,000Source | 7,025,000Source | 17,394,000Source | 7,249,000Source | 7,968,000Source | 26,494,000Source | 6,584,000Source | 9,102,000Source | 17,690,000Source | 6,118,000Source | 13,961,000Source |
| Operating Lease, Right-of-Use AssetUSD | 708,000Source | 3,469,000Source | 5,596,000Source | 1,401,000Source | 4,138,000Source | — | 2,091,000Source | 4,794,000Source | 0Source | 2,787,000Source | 5,438,000Source | 7,645,000Source |
| Other Assets, NoncurrentUSD | 5,882,000Source | 6,707,000Source | 5,007,000Source | 6,083,000Source | 6,930,000Source | 5,207,000Source | 6,283,000Source | 7,884,000Source | 5,408,000Source | 6,483,000Source | 8,128,000Source | 15,711,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 234,065,000Source | 260,782,000Source | 245,354,000Source | 259,348,000Source | 256,076,000Source | 237,079,000Source | 264,205,000Source | 251,653,000Source | 241,544,000Source | 266,798,000Source | 256,479,000Source | 237,379,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 7,862,000Source | — | 1,050,000Source | — | — | 1,050,000Source | — | — | 1,050,000Source | — | — | — |
| Common Stock, Value, IssuedUSD | 1,833,000Source | 1,517,000Source | 1,895,000Source | 1,533,000Source | 1,516,000Source | 1,886,000Source | 1,524,000Source | 1,504,000Source | 1,883,000Source | 1,521,000Source | 1,503,000Source | 1,191,000Source |
| Additional Paid in CapitalUSD | 1,942,025,000Source | 1,881,695,000Source | 1,957,358,000Source | 1,890,550,000Source | 1,878,961,000Source | 1,954,107,000Source | 1,886,981,000Source | 1,873,910,000Source | 1,951,185,000Source | 1,884,409,000Source | 1,870,525,000Source | 1,807,855,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,936,835,000Source | -1,923,257,000Source | -1,953,389,000Source | -1,919,340,000Source | -1,918,409,000Source | -1,947,900,000Source | -1,916,959,000Source | -1,909,174,000Source | -1,939,789,000Source | -1,919,594,000Source | -1,906,014,000Source | -1,795,455,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 0Source | 40,000Source | -6,000Source | -1,000Source | -8,000Source | -6,000Source | 1,000Source | -6,000Source | 4,000Source | 13,000Source | 13,000Source | -19,000Source |
| Stockholders' Equity Attributable to ParentUSD | 14,885,000Source | -40,005,000Source | 6,908,000Source | -27,258,000Source | -37,940,000Source | 9,137,000Source | -28,453,000Source | -33,766,000Source | 14,333,000Source | -33,651,000Source | -33,973,000Source | 13,572,000Source |
| Liabilities and EquityUSD | 248,950,000Source | 220,777,000Source | 252,262,000Source | 232,090,000Source | 218,136,000Source | 246,216,000Source | 235,752,000Source | 217,887,000Source | 255,877,000Source | 233,147,000Source | 222,506,000Source | 250,951,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 89,708,000Source | 85,544,000Source | 92,145,000Source | 258,601,000Source | 80,317,000Source | 90,516,000Source | 88,557,000Source | 75,378,000Source | 96,098,000Source | 91,457,000Source | 79,685,000Source | 82,355,000Source |
| Operating Lease, Liability, CurrentUSD | 780,000Source | 3,249,000Source | 200,000Source | 1,539,000Source | 3,194,000Source | — | 2,290,000Source | 3,137,000Source | 0Source | 3,037,000Source | 3,075,000Source | 2,694,000Source |
| Accounts Payable, CurrentUSD | 12,017,000Source | 10,188,000Source | 11,641,000Source | 12,037,000Source | 10,226,000Source | 8,970,000Source | 12,333,000Source | 837,000Source | 8,994,000Source | 11,709,000Source | 3,240,000Source | 3,225,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 522,000Source | 5,504,000Source | — | 1,289,000Source | — | — | 2,045,000Source | — | — | 2,800,000Source | 5,499,000Source |
| Other Liabilities, NoncurrentUSD | 4,694,000Source | 241,000Source | 5,055,000Source | 747,000Source | 241,000Source | 4,929,000Source | 682,000Source | 241,000Source | 4,808,000Source | 615,000Source | 241,000Source | 241,000Source |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 55,500,000Source | 70,900,000Source | 42,700,000Source | 40,600,000Source | 67,300,000Source | 44,800,000Source | 50,700,000Source | 71,500,000Source | 46,600,000Source | 59,300,000Source | 80,400,000Source | 84,900,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -8,111,000Source | 2,635,000Source | -20,195,000Source | — | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 529,000Source | 551,000Source | 2,314,000Source | 2,492,000Source | 2,899,000Source | 2,889,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,976,000Source | 2,511,000Source | 10,339,000Source | 12,962,000Source | 32,854,000Source | 42,980,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -5,894,000Source | -145,000Source | 10,706,000Source | 18,744,000Source | 8,088,000Source | 16,550,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 169,000Source | 3,772,000Source | 31,052,000Source | 11,050,000Source | -12,463,000Source | 6,191,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -24,000Source | 624,000Source | -2,715,000Source | 8,469,000Source | 15,000Source | -578,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,540,000Source | -8,870,000Source | -27,591,000Source | -22,529,000Source | -58,789,000Source | -146,912,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -939,000Source | 2,273,000Source | 16,009,000Source | 18,714,000Source | 17,995,000Source | -3,324,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 391,000Source | 109,000Source | 317,000Source | 1,706,000Source | 1,545,000Source | 1,825,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -51,000Source | 64,000Source | 14,427,000Source | 940,000Source | 54,107,000Source | 75,059,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -2,530,000Source | -6,533,000Source | 2,845,000Source | -2,875,000Source | 13,313,000Source | -75,177,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 43,068,000Source | 25,741,000Source | 20,721,000Source | 16,516,000Source | 26,117,000Source | 19,269,000Source | 28,647,000Source | 25,802,000Source | 28,677,000Source | 15,364,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 2,627,000Source | 636,000Source | 6,512,000Source | 4,860,000Source | 3,059,000Source | 2,250,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,852,000Source | 2,722,000Source | 3,178,000Source | 2,797,000Source | 2,976,000Source | 2,511,000Source | 10,339,000Source | 12,962,000Source | 32,854,000Source | 42,980,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | 53,000Source | 73,000Source | 210,000Source | 206,000Source | 202,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 55,500,000Source | 70,900,000Source | 42,700,000Source | 40,600,000Source | 44,800,000Source | 50,700,000Source | 46,600,000Source | 59,300,000Source | 80,400,000Source | 84,900,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 5,000Source | 1,000Source | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | 0Source | 34,000Source | — | 27,000Source | -10,000Source | -74,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -11,339,000Source | — | — | — | — | — | -11,339,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 13,980,000Source | 12,373,000Source | 11,276,000Source | 14,471,000Source | 12,145,000Source | 12,702,000Source | 54,605,000Source | 53,397,000Source | 49,014,000Source | 37,437,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | — | — | — | — | — | — | 9,605,000Source | 6,032,000Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | 1,948,000Source | 3,550,000Source | 3,364,000Source | 1,638,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -17,495,000Source | -4,848,000Source | -5,489,000Source | -2,381,000Source | -8,111,000Source | 2,635,000Source | -20,195,000Source | -13,580,000Source | -110,559,000Source | -182,024,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | -17,657,000Source | -2,052,000Source | 56,000Source | -7,366,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 3,100,000Source | 3,000,000Source | 2,900,000Source | 2,800,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -2,063,000Source | -390,000Source | -3,445,000Source | -744,000Source | -3,346,000Source | -519,000Source | 1,339,000Source | 430,000Source | 560,000Source | -6,530,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 18,307,000Source | — | 29,755,000Source | 75,145,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 38,213,000Source | 32,810,000Source | 37,666,000Source | 37,200,000Source | 34,711,000Source | 38,903,000Source | 154,904,000Source | 144,285,000Source | 127,044,000Source | 107,672,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of RevenueUSD | — | — | 11,914,000Source | 9,458,000Source | 11,572,000Source | 9,857,000Source | 10,638,000Source | 8,457,000Source | 41,347,000Source | 38,648,000Source | 65,105,000Source | 54,874,000Source |
| Operating Income (Loss)USD | — | — | -4,093,000Source | -4,458,000Source | -2,044,000Source | -1,637,000Source | -4,765,000Source | 3,154,000Source | -2,538,000Source | -11,528,000Source | -110,615,000Source | -174,658,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -2,063,000Source | -390,000Source | -3,445,000Source | -744,000Source | -3,346,000Source | -519,000Source | 1,339,000Source | 430,000Source | 560,000Source | -6,530,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -17,495,000Source | -4,848,000Source | -5,489,000Source | -2,381,000Source | -8,111,000Source | 2,635,000Source | -20,195,000Source | -13,580,000Source | -110,559,000Source | -182,024,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.1Source | -0.03Source | -0.03Source | -0.02Source | -0.04Source | 0.02Source | -0.12Source | -0.09Source | -0.8Source | -1.67Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.1Source | -0.03Source | -0.03Source | -0.02Source | -0.04Source | 0.01Source | -0.12Source | -0.09Source | -0.8Source | -1.67Source |
| Total Revenue | — | — | — | — | — | — | — | — | — | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 170,348,000Source | 152,830,000Source | 190,335,000Source | 154,020,000Source | 189,646,000Source | 153,490,000Source | 166,707,000Source | 152,449,000Source | 138,135,000Source | 108,876Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 170,348,000Source | 152,830,000Source | 190,335,000Source | 154,020,000Source | 189,646,000Source | 196,921,000Source | 166,707,000Source | 152,449,000Source | 138,135,000Source | 108,876Source |
| Interest Expense (non-operating)USD | — | — | — | — | — | — | — | — | 9,605,000Source | 6,032,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 30,392,000Source | 27,810,000Source | 28,138,000Source | 28,980,000Source | 28,838,000Source | 27,292,000Source | 116,095,000Source | 117,165,000Source | 172,554,000Source | 282,330,000Source |
| General and Administrative ExpenseUSD | — | — | 13,980,000Source | 12,373,000Source | 11,276,000Source | 14,471,000Source | 12,145,000Source | 12,702,000Source | 54,605,000Source | 53,397,000Source | 49,014,000Source | 37,437,000Source |
| Gross ProfitUSD | — | — | 26,299,000Source | 23,352,000Source | 26,094,000Source | 27,343,000Source | 24,073,000Source | 30,446,000Source | 113,557,000Source | 105,637,000Source | 61,939,000Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 3,868,000Source | 2,474,000Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | 1,948,000Source | 3,550,000Source | 3,364,000Source | 1,638,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | -17,657,000Source | -2,052,000Source | 56,000Source | -7,366,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 3,100,000Source | 3,000,000Source | 2,900,000Source | 2,800,000Source |
| Research and Development ExpenseUSD | — | — | 3,470,000Source | 4,465,000Source | 2,702,000Source | 2,934,000Source | 2,385,000Source | 2,279,000Source | 12,429,000Source | 16,683,000Source | 55,897,000Source | 107,506,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 38,213,000Source | 32,810,000Source | 37,666,000Source | 37,200,000Source | 34,711,000Source | 38,903,000Source | 154,904,000Source | 144,285,000Source | 127,044,000Source | 107,672,000Source |
| Selling and Marketing ExpenseUSD | — | — | 12,942,000Source | 10,972,000Source | 14,160,000Source | 11,575,000Source | 14,308,000Source | 12,311,000Source | 49,061,000Source | 47,085,000Source | 67,643,000Source | 82,513,000Source |
Filing attachments
hrtx-ex99_1.htm · 8-K · 2026-11-09
Exhibit 99.1 Heron Therapeutics Announces Third Quarter 2026 Financial Results • Q3 2026 net revenue of $35.3 million; ZYNRELEF® net revenue up 13.8% and APONVIE® net revenue up 49.3% compared to the third quarter of 2025 • Entered into a definitive agreement under which CorMedix Therapeutics will acquire substantially all of Heron’s assets, announced separately today CARY, N.C., November 9, 2026 (GLOBE NEWSWIRE) - Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commerc…
Read attachment ↗hrtx-ex4_1.htm · 8-K · 2026-11-09
Exhibit 4.1 AMENDMENT NO. 2 TO TAX BENEFIT PRESERVATION PLAN This Amendment No. 2 to Tax Benefit Preservation Plan (this “Amendment”) is dated as of November 8, 2026 (the “Effective Date”), and amends that certain Tax Benefit Preservation Plan, dated as of August 14, 2025, as amended by Amendment No. 1 to Tax Benefit Preservation Plan, dated as of August 13, 2026 (collectively, the “Plan”), by and between Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and Computershare Trus…
Read attachment ↗hrtx-ex99_1.htm · 8-K · 2026-11-09
Exhibit 99.1 CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care Adds four commercial-stage products - ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® - to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common stock Additional considerati…
Read attachment ↗hrtx-ex99_1.htm · S-8 · 2026-10-27
Exhibit 99.1 HERON THERAPEUTICS, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN (Effective June 11, 2026) 1. Purposes of the Plan. The purpose of this Plan is to encourage ownership in Heron Therapeutics, Inc., a Delaware corporation (the “Company”), by key personnel whose long-term employment or other service relationship with the Company is considered essential to the Company’s continued progress and, thereby, encourage recipients to act in the stockholders’ interest and share in t…
Read attachment ↗hrtx-ex99_2.htm · S-8 · 2026-10-27
Exhibit 99.2 HERON THERAPEUTICS, INC. 1997 EMPLOYEE STOCK PURCHASE PLAN (as amended through June 11, 2026) 1. PURPOSE. This Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan is designed to encourage and assist employees of Heron Therapeutics, Inc. and participating subsidiaries to acquire an equity interest in the Company through the purchase of shares of Company common stock. 2. DEFINITIONS. As used herein, the following definitions shall apply: (a) “Administrator” shall mean the…
Read attachment ↗hrtx-ex4_1.htm · 8-K · 2026-08-14
EX-4.1 2 hrtx-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 AMENDMENT NO. 1 TO TAX BENEFIT PRESERVATION PLAN This Amendment No. 1 to Tax Benefit Preservation Plan (this “Amendment”) is dated as of August 13, 2026 (the “Effective Date”), and amends that certain Tax Benefit Preservation Plan, dated as of August 14, 2025 (the “Plan”), by and between Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., a federally chartered trust company, as rights a…
Read attachment ↗